Proteolix

About Proteolix

Proteolix, Inc. was a biopharmaceutical company that specialized in discovering and developing therapies for cancer and autoimmune diseases by targeting protein degradation pathways. Founded in December 2003, the company's scientific foundation was built upon the research of co-founders Craig M. Crews from Yale University and Raymond J. Deshaies from the California Institute of Technology. They were joined by co-founders Susan Molineaux, who initially served as CEO, and Phil Whitcome, who brought extensive biotechnology industry experience. The scientific founders' deep expertise in the ubiquitin-proteasome pathway was pivotal, but it was the addition of Molineaux and Whitcome that enabled the company to secure its initial $18.2 million Series A funding by refining the business plan.

The company's business model centered on the research and development of novel proteasome inhibitors, aiming to create more effective and tolerable treatments than existing options. Proteolix's primary market was oncology, specifically focusing on hematological malignancies like multiple myeloma. The company's strategy involved advancing its lead drug candidate through rigorous clinical trials to establish safety and efficacy, with the ultimate goal of commercialization or a strategic acquisition. Revenue generation was predicated on the future sales of its developed drugs upon regulatory approval. This strategy culminated in a significant milestone in October 2009, when Onyx Pharmaceuticals acquired Proteolix in a deal valued at up to $851 million, including an upfront payment of $276 million and subsequent milestone-based payments.

Proteolix's lead product, carfilzomib (formerly PR-171), is a highly specific, irreversible proteasome inhibitor. It functions by blocking proteasomes, which are cellular complexes responsible for breaking down proteins. In cancer cells, particularly multiple myeloma cells, this inhibition leads to a buildup of proteins that triggers programmed cell death (apoptosis). Marketed as Kyprolis®, carfilzomib was developed as a second-generation inhibitor, demonstrating strong response rates and a potentially more tolerable safety profile compared to first-generation treatments. At the time of its acquisition, Proteolix had advanced carfilzomib into multiple Phase 2 clinical trials and was planning for Phase 3 studies. The company's pipeline also included other promising candidates, such as an oral proteasome inhibitor (PR-047) and a selective immunoproteasome inhibitor (PR-957) for autoimmune diseases.